India's Richest People 2026 edition · 1 director · Source: Hurun India
- #1,233 Swapnil Jatin Shah ₹1,900 Cr
Market Cap
₹966 Cr
REMUS-SM · NSE
Share Price
₹810.90
-1.11% today
Revenue
₹854 Cr
FY 2025-26 · +37.6% YoY
EBITDA
₹56.69 Cr
Margin 6.6%
Net Profit
₹36.99 Cr
FY 2025-26 · +28.0% YoY
P/E (TTM)
26.2x
P/B 2.8x
Authorised capital
₹12.5 Cr
Registered with MCA
Paid-up capital
₹11.78 Cr
Issued & subscribed
About Remus Pharmaceuticals Limited
Data last updated:
Remus Pharmaceuticals Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the wholesale trading and distribution segment of the trading and commerce sector. It was incorporated on 21 September 2015 and has been in existence for over 11 years.
Its director Swapnil Jatin Shah is #1,233 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24232GJ2015PLC084536. Its GSTIN is 24AAHCR4771P2ZQ (Gujarat). The company holds 2 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on NSE: REMUS.
The company has an authorised share capital of ₹12.5 Cr and a paid-up capital of ₹11.78 Cr. It was formerly known as Remus Pharmaceuticals Private Limited. It is led by directors including Arpit Deepakkumar Shah (Managing Director) and Roma Vinodbhai Shah (Whole-Time Director).
Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Jayantilal Park, Ahmedabad, Gujarat.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹853.63 Cr, a growth of 37.6% compared to the previous year. For the same year it recorded a net profit of ₹36.99 Cr (net margin 4.3%) and EBITDA of ₹56.69 Cr (EBITDA margin 6.6%). The net worth stands at ₹350.99 Cr (up 37.2% YoY). Total assets are valued at ₹415.42 Cr (up 35.7% YoY).
The company has about 65 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Remus Pharma. As per MCA filings, the company has open charges of ₹17.56 Cr and satisfied charges of ₹2 Cr on record. The company has 4 deals on record (2 secondary share transfers, 1 ipo, 1 funding round), with disclosed funding of ₹4.25 Cr; the latest was in May 2023. The company has 12 MSME Form 1 returns on record between 2018 and 2023, listing 325 overdue payments to 25 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website remuspharma.com.
Company details
CIN L24232GJ2015PLC084536
Registration Number 084536
Incorporation Date 21 September 2015
ROC Ahmedabad
Listing Status Listed (NSE: REMUS)
Company Status Active
Compliance Status Active Compliant
CIN history
Remus Pharmaceuticals has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24232GJ2015PLC084536, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24232GJ2015PLC084536 | Current |
| U24232GJ2015PLC084536 | Previous |
| U24232GJ2015PTC084536 | Previous |
Key People
Arpit Deepakkumar Shah Managing Director Roma Vinodbhai Shah Whole-Time Director Swapnil Jatinbhai Shah Director Recognitions & Rankings of Remus Pharmaceuticals
Contact details
Remus Pharmaceuticals Limited's registered office is in Ahmedabad, Gujarat. Its website is remuspharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address1101 To 1103 South Tower One 42 B/H Ashok Vatika Nr.Jayantilal Park Brts Ambli Bopal Roa, D, Ahmedabad, Gujarat, India – 380054
- IndustryTrading, Wholesale, Other Wholesale
To see the full contact details of Remus Pharmaceuticals Limited, buy the company report.
Comprehensive company report
Remus Pharmaceuticals Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Remus Pharmaceuticals operates one associated brand: Remus Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Remus Pharma is engaged in providing healthcare solutions globally. | remuspharma.com |
Business activity
The main business activity of Remus Pharmaceuticals is wholesale and retail trade; repair of motor vehicles and motorcycles. In detail, this covers wholesale trade, except of motor vehicles and motorcycles.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Wholesale and retail trade; repair of motor vehicles and motorcycles | 46 | Wholesale trade, except of motor vehicles and motorcycles |
To see the full business activity and turnover split of Remus Pharmaceuticals Limited, buy the company report.
Financials of Remus Pharmaceuticals Limited
FY 2025-26 filings availableRemus Pharmaceuticals Limited reported revenue of ₹853.63 Cr (up 37.6% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹854 Cr
+37.6% YoY
EBITDA
₹56.69 Cr
+24.1% YoY
Profit After Tax
₹36.99 Cr
+27.9% YoY
Net Worth
₹351 Cr
+37.2% YoY
Total Assets
₹415 Cr
+35.7% YoY
Total Debt
₹27.07 Cr
+17.8% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Income statement | |||
| Revenue | 854 | 620 | 213 |
| Revenue growth | +37.6% | +191.3% | - |
| EBITDA | 56.69 | 45.69 | 28.96 |
| EBITDA margin | +6.6% | +7.4% | +13.6% |
| Profit before tax | 59.16 | 47.34 | 30.17 |
| Net profit | 36.99 | 28.91 | 20.52 |
| Net profit margin | +4.3% | +4.7% | +9.6% |
| EPS (₹) | 39.19 | 49.35 | 139.59 |
| Balance sheet | |||
| Total assets | 415 | 306 | 190 |
| Net worth | 351 | 256 | 158 |
| Total debt | 27.07 | 22.98 | 14.23 |
| Cash & bank | 12.88 | 8.14 | 13.85 |
| Net working capital | 146 | 118 | 80.14 |
| Cash flow | |||
| Cash from operations | 18.16 | 6.98 | 3.60 |
| Cash from investing | (15.03) | (10.55) | (8.94) |
| Cash from financing | 1.47 | 6.07 | 24.37 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 93.99 | 79.16 | 63.94 | 45.03 | 24.72 | 18.42 | 11.92 |
| Revenue growth | +18.7% | +23.8% | +42.0% | +82.2% | +34.2% | +54.5% | - |
| EBITDA | 29.72 | 25.98 | 21.00 | 10.55 | 4.14 | 0.80 | 0.38 |
| EBITDA margin | +31.6% | +32.8% | +32.8% | +23.4% | +16.8% | +4.3% | +3.2% |
| Profit before tax | 33.23 | 26.64 | 22.35 | 11.42 | 4.62 | 1.40 | 1.08 |
| Net profit | 24.71 | 19.75 | 16.62 | 8.51 | 3.43 | 0.97 | 0.79 |
| Net profit margin | +26.3% | +25.0% | +26.0% | +18.9% | +13.9% | +5.3% | +6.6% |
| EPS (₹) | 20.96 | 33.79 | 113.06 | 78.37 | 34.34 | 1,059.50 | 811.60 |
| Balance sheet | |||||||
| Total assets | 333 | 247 | 158 | 27.35 | 6.77 | 3.42 | 2.46 |
| Net worth | 326 | 242 | 154 | 19.14 | 6.58 | 3.14 | 2.02 |
| Total debt | 6.20 | 4.31 | 4.12 | 7.95 | 0.19 | 0.28 | 0.36 |
| Cash & bank | 3.82 | 4.37 | 10.84 | 3.04 | 1.15 | 0.83 | 1.20 |
| Net working capital | 49.36 | 43.70 | 34.68 | 4.04 | (1.39) | (0.10) | 1.92 |
| Cash flow | |||||||
| Cash from operations | 22.30 | 15.59 | 6.31 | 5.31 | 5.04 | (0.12) | 1.30 |
| Cash from investing | (26.33) | (12.42) | (47.24) | (15.19) | (4.55) | (0.13) | (0.56) |
| Cash from financing | 0.13 | (1.42) | 41.63 | 11.77 | (0.17) | (0.11) | 0.06 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 13 Nov 2026
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue | 854 | 620 | 213 |
| Revenue growth | +37.6% | +191.3% | - |
| Other income | 6.70 | 4.98 | 2.83 |
| Total expenses | 797 | 575 | 184 |
| Employee cost | 0.00 | 13.11 | 7.32 |
| EBITDA | 56.69 | 45.69 | 28.96 |
| EBITDA margin | +6.6% | +7.4% | +13.6% |
| Depreciation | 2.76 | 1.87 | 1.12 |
| Interest | 1.47 | 1.46 | 0.50 |
| Profit before tax | 59.16 | 47.34 | 30.17 |
| Tax | 12.99 | 8.92 | 5.89 |
| Net profit | 36.99 | 28.91 | 20.52 |
| Net profit margin | +4.3% | +4.7% | +9.6% |
| EPS (₹) | 39.19 | 49.35 | 139.59 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 11.78 | 5.89 | 1.47 |
| Reserves & surplus | 339 | 250 | 156 |
| Shareholders' funds (net worth) | 351 | 256 | 158 |
| Minority interest | 36.74 | 26.69 | 17.52 |
| Secured loans | 21.37 | 19.26 | 9.99 |
| Unsecured loans | 5.70 | 3.72 | 4.24 |
| Total debt | 27.07 | 22.98 | 14.23 |
| Total liabilities | 415 | 306 | 190 |
| Assets | |||
| Gross block | 24.36 | 19.27 | 15.86 |
| Net block | 18.27 | 15.76 | 13.79 |
| Capital work in progress | 8.50 | 0.06 | 0.01 |
| Investments | 275 | 186 | 105 |
| Inventories | 72.06 | 51.56 | 43.11 |
| Sundry debtors | 140 | 108 | 115 |
| Cash & bank balances | 12.88 | 8.14 | 13.85 |
| Loans & advances | 52.33 | 53.64 | 39.94 |
| Total current assets | 277 | 221 | 212 |
| Total current liabilities | 131 | 104 | 132 |
| Net working capital | 146 | 118 | 80.14 |
| Total assets | 415 | 306 | 190 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Opening cash | 7.22 | 4.73 | 7.84 |
| Net cash from operating activities | 18.16 | 6.98 | 3.60 |
| Net cash from investing activities | (15.03) | (10.55) | (8.94) |
| Net cash from financing activities | 1.47 | 6.07 | 24.37 |
| Net change in cash | 4.60 | 2.50 | 19.03 |
| Closing cash | 12.88 | 8.14 | 13.85 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Growth | |||
| Sales growth | +37.6% | +191.3% | - |
| EBITDA growth | +24.1% | +57.8% | - |
| PBT growth | +25.0% | +56.9% | +9997.0% |
| Net income growth | +28.0% | +40.9% | - |
| Profitability & leverage | |||
| Net income margin | +5.4% | +6.2% | +11.4% |
| Return on capital employed | - | +21.6% | +17.8% |
| Return on net worth | - | +18.6% | +15.4% |
| Debt / equity | - | 0.09 | 0.09 |
| Long-term debt / equity | - | 0.02 | 0.03 |
| Interest cover | 2.73 | 3.33 | 1.80 |
| Efficiency & per share | |||
| Fixed asset turnover | - | 35.34 | 13.43 |
| Inventory turnover | - | 13.11 | 4.94 |
| Debtors turnover | - | 5.56 | 1.85 |
| EPS (₹) | 39.19 | 49.35 | 139.59 |
| Dividend per share (₹) | 0.50 | 1.50 | 6.00 |
| Book value per share (₹) | 0.00 | 434.40 | 1,072.72 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 93.99 | 79.16 | 63.94 | 45.03 | 24.72 | 18.42 | 11.92 |
| Revenue growth | +18.7% | +23.8% | +42.0% | +82.2% | +34.2% | +54.5% | - |
| Other income | 6.84 | 2.91 | 2.81 | 1.58 | 0.72 | 0.81 | 0.85 |
| Total expenses | 64.27 | 53.18 | 42.94 | 34.48 | 20.58 | 17.62 | 11.54 |
| Employee cost | 0.00 | 9.17 | 6.51 | 5.47 | 3.42 | 2.95 | 2.86 |
| EBITDA | 29.72 | 25.98 | 21.00 | 10.55 | 4.14 | 0.80 | 0.38 |
| EBITDA margin | +31.6% | +32.8% | +32.8% | +23.4% | +16.8% | +4.3% | +3.2% |
| Depreciation | 2.75 | 1.87 | 1.12 | 0.48 | 0.15 | 0.18 | 0.11 |
| Interest | 0.58 | 0.38 | 0.34 | 0.23 | 0.09 | 0.03 | 0.04 |
| Profit before tax | 33.23 | 26.64 | 22.35 | 11.42 | 4.62 | 1.40 | 1.08 |
| Tax | 8.52 | 6.74 | 5.73 | 2.91 | 1.18 | 0.35 | 0.29 |
| Net profit | 24.71 | 19.75 | 16.62 | 8.51 | 3.43 | 0.97 | 0.79 |
| Net profit margin | +26.3% | +25.0% | +26.0% | +18.9% | +13.9% | +5.3% | +6.6% |
| EPS (₹) | 20.96 | 33.79 | 113.06 | 78.37 | 34.34 | 1,059.50 | 811.60 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.78 | 5.89 | 1.47 | 1.09 | 1.00 | 0.01 | 0.01 |
| Reserves & surplus | 314 | 236 | 152 | 18.05 | 5.58 | 3.13 | 2.01 |
| Shareholders' funds (net worth) | 326 | 242 | 154 | 19.14 | 6.58 | 3.14 | 2.02 |
| Secured loans | 4.33 | 2.14 | 1.65 | 2.30 | 0.19 | 0.28 | 0.36 |
| Unsecured loans | 1.87 | 2.17 | 2.47 | 5.65 | 0.00 | 0.00 | 0.00 |
| Total debt | 6.20 | 4.31 | 4.12 | 7.95 | 0.19 | 0.28 | 0.36 |
| Total liabilities | 333 | 247 | 158 | 27.35 | 6.77 | 3.42 | 2.46 |
| Assets | |||||||
| Gross block | 13.23 | 10.51 | 7.14 | 3.50 | 0.79 | 0.72 | 0.65 |
| Net block | 7.32 | 7.01 | 5.06 | 2.54 | 0.31 | 0.39 | 0.50 |
| Capital work in progress | 0.06 | 0.06 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 |
| Investments | 297 | 209 | 127 | 20.62 | 3.07 | 0.07 | 0.00 |
| Inventories | 2.75 | 2.12 | 1.89 | 0.29 | 1.59 | 1.15 | 0.44 |
| Sundry debtors | 23.75 | 15.63 | 14.60 | 4.85 | 2.92 | 3.60 | 1.63 |
| Cash & bank balances | 3.82 | 4.37 | 10.84 | 3.04 | 1.15 | 0.83 | 1.20 |
| Loans & advances | 35.78 | 31.79 | 21.55 | 3.17 | 2.04 | 1.91 | 1.50 |
| Total current assets | 66.10 | 53.91 | 48.88 | 11.35 | 7.70 | 7.49 | 4.77 |
| Total current liabilities | 16.74 | 10.21 | 14.20 | 7.31 | 9.09 | 7.59 | 2.85 |
| Net working capital | 49.36 | 43.70 | 34.68 | 4.04 | (1.39) | (0.10) | 1.92 |
| Total assets | 333 | 247 | 158 | 27.35 | 6.77 | 3.42 | 2.46 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.46 | 1.71 | 1.01 | 1.15 | 0.83 | 1.20 | 0.39 |
| Net cash from operating activities | 22.30 | 15.59 | 6.31 | 5.31 | 5.04 | (0.12) | 1.30 |
| Net cash from investing activities | (26.33) | (12.42) | (47.24) | (15.19) | (4.55) | (0.13) | (0.56) |
| Net cash from financing activities | 0.13 | (1.42) | 41.63 | 11.77 | (0.17) | (0.11) | 0.06 |
| Net change in cash | (3.90) | 1.75 | 0.70 | 1.89 | 0.32 | (0.37) | 0.81 |
| Closing cash | 3.82 | 4.37 | 10.84 | 3.04 | 1.15 | 0.83 | 1.20 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +18.7% | +23.8% | +42.0% | +82.2% | +34.2% | +54.5% | - |
| EBITDA growth | +14.4% | +23.7% | +99.1% | +154.8% | +417.5% | +110.5% | - |
| PBT growth | +24.7% | +19.2% | +95.7% | +147.2% | +230.0% | +29.6% | +9997.0% |
| Net income growth | +25.1% | +18.8% | +95.3% | +148.1% | +253.6% | +22.8% | - |
| Revenue CAGR (3Y) | +27.8% | +47.4% | +51.4% | +55.7% | - | - | - |
| EBITDA CAGR (3Y) | +41.2% | +84.5% | +197.2% | +202.8% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +26.3% | +25.1% | +26.0% | +18.9% | +13.9% | +5.7% | +6.6% |
| Return on capital employed | - | +13.3% | +24.5% | +68.2% | +92.3% | +49.0% | +45.9% |
| Return on net worth | - | +10.1% | +19.3% | +66.1% | +70.6% | +41.1% | +40.1% |
| Debt / equity | - | 0.02 | 0.07 | 0.32 | 0.05 | 0.12 | 0.18 |
| Long-term debt / equity | - | 0.02 | 0.06 | 0.28 | 0.03 | 0.09 | 0.14 |
| Interest cover | 2.15 | 1.58 | 1.71 | 2.28 | 2.26 | 4.84 | 14.81 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 8.97 | 12.02 | 20.99 | 32.74 | 26.89 | 18.34 |
| Inventory turnover | - | 39.48 | 58.66 | 47.90 | 18.04 | 23.17 | 27.09 |
| Debtors turnover | - | 5.24 | 6.57 | 11.59 | 7.58 | 7.04 | 7.31 |
| EPS (₹) | 20.96 | 33.79 | 113.06 | 78.37 | 34.34 | 1,059.50 | 811.60 |
| Dividend per share (₹) | 0.50 | 1.50 | 6.00 | 2.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 411.24 | 1,044.56 | 176.36 | 65.78 | 3,143.70 | 2,020.30 |
To see the full year-wise statements and ratios of Remus Pharmaceuticals Limited, buy the company report.
Board of directors of Remus Pharmaceuticals Limited
Remus Pharmaceuticals has 8 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Swapnil Jatinbhai Shah Also directs: Espee Therapeutics LLP, Aelius Projects LLP, Senores Pharmaceuticals Limited and 4 more | Director | 21 Sep 2015 | 11 Years 1 Months | Current |
| Roma Vinodbhai Shah Also directs: Relius Lifesciences Private Limited | Whole-Time Director | 21 Sep 2015 | 11 Years 1 Months | Current |
| Arpit Deepakkumar Shah | Managing Director | 21 Sep 2015 | 11 Years 1 Months | Current |
| Anar Swapnil Shah Also directs: Espee Global Clinical Trial Services Private Limited, Espee Therapeutics LLP, Aelius Projects LLP and 5 more | Director | 30 Dec 2020 | 5 Years 10 Months | Current |
| Sanjana Sanjeev Shah | Director | 06 Jan 2023 | 3 Years 10 Months | Current |
| Balwant Purohit | Director | 06 Jan 2023 | 3 Years 10 Months | Current |
Showing 6 of 8 current directors. View all directors
Auditor
Remus Pharmaceuticals Limited is audited by PANKAJ R SHAH & ASSOCIATES for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| PANKAJ R SHAH & ASSOCIATES | FY 2025 | 107361W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 71.00%, foreign institutional investors hold 5.30%, domestic institutional investors hold 0.80% and retail and other public shareholders hold 22.90%.
Sep 2026
QUARTER
71.00% Promoters
0.80% DII (Domestic Institutional)
5.30% FII (Foreign Institutional)
22.90% Retail & Others
Promoter holding - history
Now 71.00% · Sep 2026High 71.00% · Sep 2026Low 70.80% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 71.00% | 70.90% | 70.80% | 70.80% |
| Public | 29.00% | 29.10% | 29.20% | 29.20% |
Charges & borrowings
Open charges
₹17.56 Cr
Satisfied charges
₹2 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 18 Aug 2026 | 101405317 | Others | ₹1.9 Cr | Open | |
| 27 Oct 2025 | 101188093 | Others | ₹49.9 Lakh | Open | |
| 26 Sep 2025 | 101185694 | Hdfc Bank Limited | ₹10.48 Cr | Open | |
| 26 Jun 2025 | 101117662 | Hdfc Bank Limited | ₹2.19 Cr | Open | |
| 02 Sep 2024 | 100969089 | Hdfc Bank Limited | ₹1 Cr | Open |
To see the full charge records of Remus Pharmaceuticals Limited, buy the company report.
Total charge records: 7 View all charges
Deals & funding
Remus Pharmaceuticals Limited has 4 deals on record (2 secondary share transfers, 1 ipo, 1 funding round), with disclosed funding of ₹4.25 Cr; the latest was in May 2023.
Total deals
4
Secondary share transfers
2
IPO
1
Funding round
1
Disclosed funding
₹4.25 Cr
Deals on record (4 of 4)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2023 | IPO | ₹47.69 Cr | Investors: Chhatisgarh Investments Limited , NAV Capital VCC |
| Dec 2022 | Funding round | ₹4.25 Cr | Investors: 4 individuals |
| Mar 2020 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: Espee Lifescience Private Limited, an individual |
| Mar 2016 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: Espee Lifescience Private Limited |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Remus Pharmaceuticals Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
Remus Pharmaceuticals Limited has 12 MSME Form 1 returns on record between 2018 and 2023, listing 325 overdue payments to 25 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 25)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Chase Logistics Private Limited | |||
| Suraj Print Pack Private Limited | |||
| an individual supplier | |||
| Aelius Projects LLP | |||
| Auracare Pharma Private Limited |
To see the full MSME payment records of Remus Pharmaceuticals Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Remus Pharmaceuticals Limited has a workforce of 65 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Employee count
65
Active EPFO establishments
1
Employee growth
6.6%
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 65 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 |
To see the full employee and EPFO history of Remus Pharmaceuticals Limited, buy the company report.
GST
Remus Pharmaceuticals has 2 GST registrations: 1 active and 1 cancelled or inactive.
Total GSTINs
2
Active
1
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAHCR4771P2ZQ | Gujarat | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Remus Pharmaceuticals Limited, buy the company report.
Recent activity
Remus Pharmaceuticals Limited has 15 board changes on record since 2015: 8 appointments and 7 cessations. The latest: Ashutosh Naginbhai Valani was appointed as Additional Director on 02 Sep 2026.
Appointed
Ashutosh Naginbhai Valani was appointed as Additional Director.
Charges
A charge with Others amounted to Rs. 1.90 Cr with Charge ID 101405317 was registered on 18 Aug 2026.
Filing
Remus Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge with Others amounted to Rs. 0.50 Cr with Charge ID 101188093 was registered on 27 Oct 2025.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 10.48 Cr with Charge ID 101185694 was registered on 26 Sep 2025.
AGM
Remus Pharmaceuticals Limited last Annual general meeting of members was held on 25 Sep 2025 as per latest MCA records.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 2.19 Cr with Charge ID 101117662 was registered on 26 Jun 2025.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 1.00 Cr with Charge ID 100969089 was registered on 02 Sep 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 1.50 Cr with Charge ID 100881296 was registered on 26 Feb 2024.
Charges
A charge registered on 29 Oct 2022 via Charge ID 100627417 with Others was fully satisfied on 15 Mar 2023.
Ceased
Balwant Purohit ceased to be Additional Director.
Ceased
Sanjana Sanjeev Shah ceased to be Additional Director.
14 earlier events are in the company report.
News
Frequently asked questions
Remus Pharmaceuticals is an active public limited company based in Ahmedabad, Gujarat, India. The company works in wholesale, within the trading industry. It was incorporated on 21 September 2015 (11+ years old) and is registered under CIN L24232GJ2015PLC084536. Listed on NSE: REMUS.
Remus Pharmaceuticals reported revenue of ₹853.63 Cr for FY 2025-26 (up 37.6% YoY) based on consolidated financials.
Remus Pharmaceuticals has 8 current directors:
- Arpit Deepakkumar Shah - Managing Director
- Roma Vinodbhai Shah - Whole-Time Director
- Swapnil Jatinbhai Shah - Director
- Anar Swapnil Shah - Director
- Sanjana Sanjeev Shah - Director
- Balwant Purohit - Director
- Vishrut Chandramauli Pathak - Director
- Ashutosh Naginbhai Valani - Additional Director
The latest financial statements of Remus Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 September 2025. Year-wise statements from FY 2016 are in the company report.
The GSTIN of Remus Pharmaceuticals is 24AAHCR4771P2ZQ, registered in Gujarat. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Remus Pharmaceuticals is L24232GJ2015PLC084536. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Remus Pharmaceuticals is a listed company as per MCA records. Its shares are listed on NSE (symbol: REMUS).
Remus Pharmaceuticals was incorporated on 21 September 2015, making it 11+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Remus Pharmaceuticals has 4 deals on record (2 secondary share transfers, 1 ipo, 1 funding round), with disclosed funding of ₹4.25 Cr; the latest was in May 2023.
Ashutosh Naginbhai Valani was appointed as Additional Director on 02 Sep 2026. Balwant Purohit ceased to be Additional Director on 28 Feb 2023. Sanjana Sanjeev Shah ceased to be Additional Director on 28 Feb 2023. Remus Pharmaceuticals has 15 board changes on record in total.
Remus Pharmaceuticals has 12 MSME Form 1 returns on record between 2018 and 2023, listing 325 overdue payments to 25 micro and small suppliers. The latest return was filed on 29 Oct 2023.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages